Alentis Therapeutics AG

Based in Switzerland, Alentis Therapeutics AG focuses on developing innovative antibody-based treatments for cancer and fibrosis, leveraging advanced therapeutic technologies to address unmet medical needs. Alentis Therapeutics AG specializes in targeted therapies for cancer and fibrosis. Founded in 2019 and headquartered in Allschwil, Switzerland, the company has undergone strategic pivots to refine its focus on innovative treatments. Co-founded by Neil Goldsmith and Thomas Baumert, Alentis has completed five deals and recently raised EUR 164.

500 mn in a Series D funding round with participation from notable investors including Avego Bioscience Capital and Novo Holdings. The current CEO is Nathalie Graf-Tschupp. Alentis Therapeutics specializes in developing innovative treatments targeting cancer and fibrosis through its core product offerings of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies. Their lead clinical candidates include the ADC ALE.

P02, designed for squamous cancers, and the monoclonal antibody lixudebart, aimed at organ fibrosis. These products function by specifically targeting Claudin-1, which plays a pivotal role in tumor cell signaling and the rigidity of the extracellular matrix, thereby promoting the selective killing of cancer cells and reversing fibrotic conditions. Alentis Therapeutics primarily serves oncologists, hospitals, and healthcare providers in North America and Europe, focusing on markets where the need for advanced cancer therapies and fibrosis treatments is critical. Alentis Therapeutics generates revenue through strategic partnerships and clinical collaborations aimed at advancing their therapeutic pipeline.

The structure of transactions typically involves agreements with pharmaceutical companies and research institutions, which may include co-development and licensing deals for their flagship products like ALE. P02 and lixudebart. These partnerships facilitate funding for ongoing clinical trials and research initiatives, contributing to the company's financial stability. While specific pricing plans are not disclosed, the revenue model is based on milestone payments and royalties derived from successful commercialization of their therapies in oncology and fibrosis treatment markets.

Alentis Therapeutics AG is focused on advancing its clinical pipeline with new products aimed at addressing significant medical needs in oncology and fibrosis. The company plans to expand its market presence in North America and Europe by 2025. Recent funding from the EUR 164. 500 mn Series D round will support ongoing clinical trials and potentially accelerate the development of new therapeutic candidates.

Additionally, Alentis has engaged with new investor Kinled Holding to enhance its strategic initiatives.